Assessment of EGFR and KRAS mutation status from FNAs and core-needle biopsies of non-small cell lung cancer

Cancer Cytopathology

Volumn 123, Issue 4, 2015, Pages 230-236

  Lozano, Maria D ^a   Labiano, Tania ^a   Echeveste, Jose ^a   Gurpide, Alfonso ^a   Martín Algarra, Salvador ^a   Zhang, Guili ^b   Sharma, Abha ^b   Palma, John F ^b  

^a UNIVERSITY CLINIC OF NAVARRA   (Spain)

^b ROCHE MOLECULAR SYSTEMS   (United States)

Author keywords

cytodiagnosis; fine needle biopsy; minimally invasive diagnostic procedures; non small cell lung carcinoma

Indexed keywords

DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; EOSIN; HEMATOXYLIN; KRAS PROTEIN, HUMAN; ONCOPROTEIN; RAS PROTEIN;

ADULT; AGED; ARTICLE; BIOPSY; CONTROLLED STUDY; CORE NEEDLE BIOPSY; EPIDERMAL GROWTH FACTOR RECEPTOR GENE; EXON; FEMALE; FINE NEEDLE ASPIRATION BIOPSY; GENE MUTATION; HUMAN; HUMAN TISSUE; LUNG BIOPSY; MALE; MUTATION RATE; NON SMALL CELL LUNG CANCER; ONCOGENE K RAS; POLYMERASE CHAIN REACTION; POLYMERASE CHAIN REACTION SYSTEM; PRIORITY JOURNAL; SEQUENCE ANALYSIS; CARCINOMA, NON-SMALL-CELL LUNG; COMPARATIVE STUDY; CYTOLOGY; EARLY DIAGNOSIS; FEASIBILITY STUDY; GENETICS; LARGE CORE NEEDLE BIOPSY; LUNG NEOPLASMS; MIDDLE AGED; MUTATION; PAPANICOLAOU TEST; PATHOLOGY; PROCEDURES; RETROSPECTIVE STUDY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BIOPSY, FINE-NEEDLE; BIOPSY, LARGE-CORE NEEDLE; CARCINOMA, NON-SMALL-CELL LUNG; CYTOLOGICAL TECHNIQUES; EARLY DETECTION OF CANCER; EOSINE YELLOWISH-(YS); FEASIBILITY STUDIES; FEMALE; HEMATOXYLIN; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; PAPANICOLAOU TEST; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES;

EID: 84926655852     PISSN: 1934662X     EISSN: 19346638     Source Type: Journal    
DOI: 10.1002/cncy.21513     Document Type: Article

References (32)

1. World Health Organization. Global Health Observatory Data Repository. Available at: http://apps.who.int/gho/data/view.main, Accessed August 8, 2014.
2. World Health Organization, International Agency for Research on Cancer. GLOBOCAN 2012: Estimated Cancer Incidence, Mortality, and Prevalence Worldwide in 2012. Available at: http://globocan.iarc.fr/Pages/fact-sheets-cancer.aspx. Accessed August 8, 2014.
3. Howlader N, Noone AM, Krapcho M, et al., SEER Cancer Statistics Review, 1975-2010. Available at: http://seer.cancer.gov/csr/1975-2010/. Accessed August 8, 2014.
4. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer. Version 4.2014. Available at: http://www.nccn.org/professionals/physician-gls/pdf/nscl.pdf. Accessed August 8, 2014.
5. Socinski MA,. The emerging role of biomarkers in advanced non-small-cell lung cancer. Clin Lung Cancer. 2010; 11: 149-159.
6. Mitsudomi T, Yatabe Y,. Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer. Cancer Sci. 2007; 98: 1817-1824.
7. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al., Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005; 353: 123-132.
8. Riely GJ, Ladanyi M,. KRAS mutations: an old oncogene becomes a new predictive biomarker. J Mol Diagn. 2008; 10: 493-495.
9. Mao C, Qiu LX, Liao RY, et al., KRAS mutations and resistance to EGFR-TKIs treatment in patients with non-small cell lung cancer: a meta-analysis of 22 studies. Lung Cancer. 2010; 69: 272-278.
10. Morgensztern D, Ng SH, Gao F, Govindan R,. Trends in stage distribution for patients with non-small cell lung cancer: a National Cancer Database survey. J Thorac Oncol. 2010; 5: 29-33.
11. Lozano MD, Zulueta JJ, Echeveste JI, et al., Assessment of epidermal growth factor receptor and K-ras mutation status in cytological stained smears of non-small cell lung cancer patients: correlation with clinical outcomes. Oncologist. 2011; 16: 877-885.
12. da Cunha Santos G, Ajaj Saieg M, Geddie W, Leighl N,. EGFR gene status in cytological samples of non-small cell lung cancer. Cancer Cytopathol. 2011; 119: 80-91.
13. Allegrini S, Antona J, Mezzapelle R, et al., Epidermal growth factor receptor gene analysis with a highly sensitive molecular assay in routine cytologic specimens of lung adenocarcinoma. Am J Clin Pathol. 2012; 138: 377-381.
14. Betz BL, Roh MH, Weigelin HC, et al., The application of molecular diagnostic studies interrogating EGFR and KRAS mutations to stained cytologic smears of lung carcinoma. Am J Clin Pathol. 2011; 136: 564-571.
15. Mitiushkina NV, Iyevleva AG, Poltoratskiy AN, et al., Detection of EGFR mutations and EML4-ALK rearrangements in lung adenocarcinomas using archived cytological slides. Cancer Cytopathol. 2013; 121: 370-376.
16. Pang B, Matthias D, Ong CW, et al., The positive impact of cytological specimens for EGFR mutation testing in non-small cell lung cancer: a single South East Asian laboratory's analysis of 670 cases. Cytopathology. 2012; 23: 229-236.
17. Boldrini L, Gisfredi S, Ursino S, et al., Mutational analysis in cytological specimens of advanced lung adenocarcinoma: a sensitive method for molecular diagnosis. J Thorac Oncol. 2007; 2: 1086-1090.
18. Nomoto K, Tsuta K, Takano T, et al., Detection of EGFR mutations in archived cytologic specimens of non-small cell lung cancer using high-resolution melting analysis. Am J Clin Pathol. 2006; 126: 608-615.
19. Cai G, Wong R, Chhieng D, et al., Identification of EGFR mutation, KRAS mutation, and ALK gene rearrangement in cytological specimens of primary and metastatic lung adenocarcinoma. Cancer Cytopathol. 2013; 121: 500-507.
20. Heymann JJ, Bulman WA, Maxfield RA, et al., Molecular testing guidelines for lung adenocarcinoma: utility of cell blocks and concordance between fine-needle aspiration cytology and histology samples [serial online]. Cytojournal. 2014; 11: 12.
21. Lewandowska MA, Jozwicki W, Jochymski C, Kowalewski J,. Application of PCR methods to evaluate EGFR, KRAS and BRAF mutations in a small number of tumor cells in cytological material from lung cancer patients. Oncol Rep. 2013; 30: 1045-1052.
22. Billah S, Stewart J, Staerkel G, Chen S, Gong Y, Guo M,. EGFR and KRAS mutations in lung carcinoma: molecular testing by using cytology specimens. Cancer Cytopathol. 2011; 119: 111-117.
23. Roche Molecular Systems. cobas EGFR Mutation Test CE-IVD [package insert]. Branchburg, NJ: Roche Molecular Systems, Inc.; 2011.
24. Roche Molecular Systems. cobas KRAS Mutation Test CE-IVD [package insert]. Branchburg, NJ: Roche Molecular Systems, Inc.; 2011.
25. Kern JA, Clamon GH,. Lung Cancer. Philadelphia, PA: Lippincott Williams & Wilkins; 1997.
26. Shigematsu H, Lin L, Takahashi T, et al., Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst. 2005; 97: 339-346.
27. Dearden S, Stevens J, Wu YL, Blowers D,. Mutation incidence and coincidence in non-small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap). Ann Oncol. 2013; 24: 2371-2376.
28. Monzon FA, Ogino S, Hammond ME, et al., The role of KRAS mutation testing in the management of patients with metastatic colorectal cancer. Arch Pathol Lab Med. 2009; 133: 1600-1606.
29. Li J, Wang L, Mamon H, et al., Replacing PCR with COLD-PCR enriches variant DNA sequences and redefines the sensitivity of genetic testing. Nat Med. 2008; 14: 579-584.
30. Ogino S, Kawasaki T, Brahmandam M, et al., Sensitive sequencing method for KRAS mutation detection by pyrosequencing. J Mol Diagn. 2005; 7: 413-421.
31. Baik CS, Pritchard CC, Eaton KD, Chow LQ,. EGFR mutations in squamous cell lung cancer in never-smokers. J Thorac Oncol. 2013; 8: e6-e7.
32. Rekhtman N, Paik PK, Arcila ME, et al., Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of lung: lack of EGFR/KRAS and presence of PIK3CA/AKT1 mutations. Clin Cancer Res. 2012; 18: 1167-1176.